Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol
Walter Filgueira de Azevedo1, Fernanda Canduri, Nelson José Freitas da Silveira
1Departamento de Física, IBILCE, UNESP, São José do Rio Preto, SP 15054-000, Brazil. walterfa@df.ibilce.unsep.br
Abstract:
Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. The complex CDK9-cyclin T1 controls the elongation phase of transcription by RNA polymerase II. The present work describes a molecular model for the binary complex CDK9-flavopiridol. This structural model indicates that the inhibitor strongly binds to the ATP-binding pocket of CDK9 and the structural comparison of the complex CDK2-flavopiridol correlates the structural differences with differences in inhibition of these CDKs by flavopiridol. This structure opens the possibility of testing new inhibitor families, in addition to new substituents for the already known leading structures such as flavones and adenine derivatives.
More Related Videos
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
Published on: September 26, 2019
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Related Concept Videos
Positive Regulator Molecules
Negative Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
Inhibition of CDK Activity
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
